organization · Reporting owner
A2A Pharmaceuticals, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Biomea Fusion, Inc.
Report date May 31, 2023 · Filed June 02, 2023
Section 16 reporting ended · disclosed 2023-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,500,000 |
Ending reported balance
After 2023-06-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-31 · Sale · Disposed 75,000 · Balance 3,550,000 F1: A total of 75,000 shares were sold at an average price of 33.81 in multiple transactions ranging from 33.44 to 34.43. Details of the specific transactions are available upon request. Row 2 · 2023-06-01 · Sale · Disposed 50,000 · Balance 3,500,000 F2: A total of 50,000 shares were sold at an average price of 34.5633 in multiple transactions ranging from 34.50 to 35.02 Details of the specific transactions are available upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 75,000 shares were sold at an average price of 33.81 in multiple transactions ranging from 33.44 to 34.43. Details of the specific transactions are available upon request.
F2: A total of 50,000 shares were sold at an average price of 34.5633 in multiple transactions ranging from 34.50 to 35.02 Details of the specific transactions are available upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2023 Filed Jun 2, 2023 21:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 50,000 | $34.56 | $1,728,165.00 |
DisclosureSEC source: 0001859061-23-000007 · primary_doc.xml · nonDerivative · entry 2 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500,000 F2 · price: A total of 50,000 shares were sold at an average price of 34.5633 in multiple transactions ranging from 34.50 to 35.02 Details of the specific transactions are available upon request. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 75,000 | $33.81 | $2,535,750.00 |
DisclosureSEC source: 0001859061-23-000007 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,550,000 F1 · price: A total of 75,000 shares were sold at an average price of 33.81 in multiple transactions ranging from 33.44 to 34.43. Details of the specific transactions are available upon request. Read SEC document |
| May 12, 2023 Filed May 17, 2023 11:13 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 25,000 | $33.84 | $846,000.00 |
DisclosureSEC source: 0001859061-23-000006 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,625,000 F1 · price: A total of 25,000 shares were sold at an average price of 33.84 in multiple transactions in a range of 33.50 to 34.50. Details of the specific transactions are available upon request. Read SEC document |
| May 09, 2023 Filed May 10, 2023 21:19 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 150,000 | $34.50 | $5,175,720.00 |
DisclosureSEC source: 0001859061-23-000005 · primary_doc.xml · nonDerivative · entry 2 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,650,000 F2 · price: A total of 150,000 shares were sold at an average price of 34.508 in multiple transactions in a range of 33.61 to 35.64. Details of the specific transactions are available upon request. Read SEC document |
| May 08, 2023 Filed May 10, 2023 21:19 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 100,000 | $33.99 | $3,399,310.00 |
DisclosureSEC source: 0001859061-23-000005 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,800,000 F1 · price: A total of 100,000 shares were sold at an average price of 33.9931 in multiple transactions in a range of 33.01 to 34.855. Details of the specific transactions are available upon request. Read SEC document |
| April 20, 2023 Filed Apr 26, 2023 12:36 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 200,000 | $29.12 | $5,823,760.00 |
DisclosureSEC source: 0001859061-23-000004 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900,000 F1 · price: A total of 200,000 shares were sold at an average price of 29.1188 in multiple transactions in a range of 28.85 to 29.495. Details of the specific transactions are available upon request Read SEC document |
| March 31, 2023 Filed Apr 6, 2023 23:31 UTC Amendment | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 200,000 | $31.25 | $6,250,000.00 |
DisclosureSEC source: 0001859061-23-000003 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100,000 F1 · price: A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64. Additional details of the individual transactions are available upon request. Read SEC document |
| March 31, 2023 Filed Apr 6, 2023 22:43 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 200,000 | $31.25 | $6,250,000.00 |
DisclosureSEC source: 0001859061-23-000002 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100,000 F1 · price: A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64 Read SEC document |
| August 16, 2022 Filed Aug 19, 2022 10:56 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | PurchaseCommon Stock | 30,684 | $13.87 | $425,648.45 |
DisclosureSEC source: 0001859061-22-000002 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300,000 F1 · shares: Shares were sold in multiple transaction in a range of prices from 13.65 to 14.01 and an average price of 13.872. Details of the specific trades are available upon request Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 23:16 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 34,658 | $11.21 | $388,516.18 |
DisclosureSEC source: 0001859061-22-000001 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330,684 Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 11:51 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | SaleCommon Stock | 34,658 | $11.76 | $407,578.08 |
DisclosureSEC source: 0001856641-22-000001 · primary_doc.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,365,342 Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 20:05 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | PurchaseCommon Stock | 34,658 | $10.96 | $379,851.68 |
DisclosureSEC source: 0000899243-21-036769 · doc4.xml · nonDerivative · entry 1 A2A Pharmaceuticals, Inc. · CIK 0001859061 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400,000 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and is an affiliate of the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.